Maarten van der Doelen
Chapter 5
Patients (n = 37)
Patients (n = 38)
Figure 2. Waterfall plots showing percentages change in alkaline phosphatase (ALP) and prostate-specific antigen (PSA). A-C . Percentage change in ALP from baseline to week 12, from baseline to end of therapy and maximum percentage change in ALP from baseline during therapy. D-F . Percentage change in PSA from baseline to week 12, from baseline to end of therapy and maximum percentage change in PSA from baseline during therapy.
0
0
75
50
25
50
-25
-50
-75
-50
100
550
500
450
400
350
300
250
200
150
100
-100
-100
C
F
Maximum percentage change in ALP from baseline during therapy
Maximum percentage change in PSA from baseline during therapy
Patients (n = 34)
Patients (n = 32)
0
0
75
50
25
50
-25
-50
-75
-50
100
550
500
450
400
350
300
250
200
150
100
-100
-100
B
E
Percentage change in ALP from baseline to end of therapy
Percentage change in PSA from baseline to end of therapy
Patients (n = 34)
Patients (n = 34)
0
0
50
25
50
-25
-50
-75
-50
550
500
450
400
350
300
250
200
150
100
-100
-100
A
D
Percentage change in ALP from baseline to week 12
Percentage change in PSA from baseline to week 12
146
Made with FlippingBook - professional solution for displaying marketing and sales documents online